Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study

Limited data concerning the development of autoimmune skin diseases after COVID-19 vaccination are currently available. Recently, a few reports described the development, worsening or recurrence of alopecia areata after the administration of COVID-19 vaccines. High variability in terms of disease on...

Full description

Saved in:

Bibliographic Details
Published in:	Vaccines (Basel) Vol. 10; no. 9; p. 1467
Main Authors:	Tassone, Francesco, Cappilli, Simone, Antonelli, Flaminia, Zingarelli, Ruggiero, Chiricozzi, Andrea, Peris, Ketty
Format:	Journal Article
Language:	English
Published:	Basel MDPI AG 01.09.2022 MDPI
Subjects:	Alopecia alopecia areata Autoimmune diseases Baldness Case Report Coronaviruses Corticoids Corticosteroids COVID-19 COVID-19 vaccines Cross-sectional studies Disease Dosage and administration Hair loss Health services Immunotherapy Medical records Minoxidil Pandemics Patient outcomes Patients Prevention Regrowth Risk factors SARS-CoV-2 Scalp Severe acute respiratory syndrome coronavirus 2 Skin diseases Thyroid gland Tofacitinib vaccine Italy
ISSN:	2076-393X, 2076-393X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Limited data concerning the development of autoimmune skin diseases after COVID-19 vaccination are currently available. Recently, a few reports described the development, worsening or recurrence of alopecia areata after the administration of COVID-19 vaccines. High variability in terms of disease onset following vaccination as well as the heterogeneous topical and/or systemic treatment approaches have been described. Methods: All patient-related data and images were obtained as part of clinical routine. Diagnosis of alopecia areata was established according to clinical and trichoscopic findings, along with the exclusion of common differential diagnoses. Results. Twenty-four patients, 20 females (83.3%) and four males (16.7%), with a mean age of 39.1 years (age range: 14–66 years), were examined for the occurrence of alopecia areata within 16 weeks after COVID-19 vaccination. Out of 24, 14 patients (58.3%) experienced a patchy alopecia areata, while an extensive disease occurred in 10/24 patients (41.7%): six patients with whole scalp involvement (alopecia areata totalis) and four patients with the whole body affected (alopecia areata universalis). Twelve patients reported a history of autoimmune disease (50%). Treatment with topical corticosteroid was performed in almost all patients with patchy alopecia areata, whilst it was associated with systemic drugs (corticosteroids, minoxidil, cyclosporin) in the case of generalized alopecia areata and alopecia areata universalis. Mean baseline values of Severity of Alopecia Tool (SALT) score decreased from 43.4 to 36.6 after 12 weeks of treatment, with evidence of hair regrowth in 16/21 patients. Conclusion. This study described the occurrence of alopecia areata after COVID-19 vaccination and its management that implicates the use of both topical and systemic therapies.
AbstractList	Limited data concerning the development of autoimmune skin diseases after COVID-19 vaccination are currently available. Recently, a few reports described the development, worsening or recurrence of alopecia areata after the administration of COVID-19 vaccines. High variability in terms of disease onset following vaccination as well as the heterogeneous topical and/or systemic treatment approaches have been described. Methods: All patient-related data and images were obtained as part of clinical routine. Diagnosis of alopecia areata was established according to clinical and trichoscopic findings, along with the exclusion of common differential diagnoses. Results. Twenty-four patients, 20 females (83.3%) and four males (16.7%), with a mean age of 39.1 years (age range: 14-66 years), were examined for the occurrence of alopecia areata within 16 weeks after COVID-19 vaccination. Out of 24, 14 patients (58.3%) experienced a patchy alopecia areata, while an extensive disease occurred in 10/24 patients (41.7%): six patients with whole scalp involvement (alopecia areata totalis) and four patients with the whole body affected (alopecia areata universalis). Twelve patients reported a history of autoimmune disease (50%). Treatment with topical corticosteroid was performed in almost all patients with patchy alopecia areata, whilst it was associated with systemic drugs (corticosteroids, minoxidil, cyclosporin) in the case of generalized alopecia areata and alopecia areata universalis. Mean baseline values of Severity of Alopecia Tool (SALT) score decreased from 43.4 to 36.6 after 12 weeks of treatment, with evidence of hair regrowth in 16/21 patients. Conclusion. This study described the occurrence of alopecia areata after COVID-19 vaccination and its management that implicates the use of both topical and systemic therapies.Limited data concerning the development of autoimmune skin diseases after COVID-19 vaccination are currently available. Recently, a few reports described the development, worsening or recurrence of alopecia areata after the administration of COVID-19 vaccines. High variability in terms of disease onset following vaccination as well as the heterogeneous topical and/or systemic treatment approaches have been described. Methods: All patient-related data and images were obtained as part of clinical routine. Diagnosis of alopecia areata was established according to clinical and trichoscopic findings, along with the exclusion of common differential diagnoses. Results. Twenty-four patients, 20 females (83.3%) and four males (16.7%), with a mean age of 39.1 years (age range: 14-66 years), were examined for the occurrence of alopecia areata within 16 weeks after COVID-19 vaccination. Out of 24, 14 patients (58.3%) experienced a patchy alopecia areata, while an extensive disease occurred in 10/24 patients (41.7%): six patients with whole scalp involvement (alopecia areata totalis) and four patients with the whole body affected (alopecia areata universalis). Twelve patients reported a history of autoimmune disease (50%). Treatment with topical corticosteroid was performed in almost all patients with patchy alopecia areata, whilst it was associated with systemic drugs (corticosteroids, minoxidil, cyclosporin) in the case of generalized alopecia areata and alopecia areata universalis. Mean baseline values of Severity of Alopecia Tool (SALT) score decreased from 43.4 to 36.6 after 12 weeks of treatment, with evidence of hair regrowth in 16/21 patients. Conclusion. This study described the occurrence of alopecia areata after COVID-19 vaccination and its management that implicates the use of both topical and systemic therapies. BackgroundLimited data concerning the development of autoimmune skin diseases after COVID-19 vaccination are currently available. Recently, a few reports described the development, worsening or recurrence of alopecia areata after the administration of COVID-19 vaccines. High variability in terms of disease onset following vaccination as well as the heterogeneous topical and/or systemic treatment approaches have been described. Methods: All patient-related data and images were obtained as part of clinical routine. Diagnosis of alopecia areata was established according to clinical and trichoscopic findings, along with the exclusion of common differential diagnoses. Results. Twenty-four patients, 20 females (83.3%) and four males (16.7%), with a mean age of 39.1 years (age range: 14–66 years), were examined for the occurrence of alopecia areata within 16 weeks after COVID-19 vaccination. Out of 24, 14 patients (58.3%) experienced a patchy alopecia areata, while an extensive disease occurred in 10/24 patients (41.7%): six patients with whole scalp involvement (alopecia areata totalis) and four patients with the whole body affected (alopecia areata universalis). Twelve patients reported a history of autoimmune disease (50%). Treatment with topical corticosteroid was performed in almost all patients with patchy alopecia areata, whilst it was associated with systemic drugs (corticosteroids, minoxidil, cyclosporin) in the case of generalized alopecia areata and alopecia areata universalis. Mean baseline values of Severity of Alopecia Tool (SALT) score decreased from 43.4 to 36.6 after 12 weeks of treatment, with evidence of hair regrowth in 16/21 patients. Conclusion. This study described the occurrence of alopecia areata after COVID-19 vaccination and its management that implicates the use of both topical and systemic therapies. Limited data concerning the development of autoimmune skin diseases after COVID-19 vaccination are currently available. Recently, a few reports described the development, worsening or recurrence of alopecia areata after the administration of COVID-19 vaccines. High variability in terms of disease onset following vaccination as well as the heterogeneous topical and/or systemic treatment approaches have been described. Methods: All patient-related data and images were obtained as part of clinical routine. Diagnosis of alopecia areata was established according to clinical and trichoscopic findings, along with the exclusion of common differential diagnoses. Results. Twenty-four patients, 20 females (83.3%) and four males (16.7%), with a mean age of 39.1 years (age range: 14–66 years), were examined for the occurrence of alopecia areata within 16 weeks after COVID-19 vaccination. Out of 24, 14 patients (58.3%) experienced a patchy alopecia areata, while an extensive disease occurred in 10/24 patients (41.7%): six patients with whole scalp involvement (alopecia areata totalis) and four patients with the whole body affected (alopecia areata universalis). Twelve patients reported a history of autoimmune disease (50%). Treatment with topical corticosteroid was performed in almost all patients with patchy alopecia areata, whilst it was associated with systemic drugs (corticosteroids, minoxidil, cyclosporin) in the case of generalized alopecia areata and alopecia areata universalis. Mean baseline values of Severity of Alopecia Tool (SALT) score decreased from 43.4 to 36.6 after 12 weeks of treatment, with evidence of hair regrowth in 16/21 patients. Conclusion. This study described the occurrence of alopecia areata after COVID-19 vaccination and its management that implicates the use of both topical and systemic therapies.
Audience	Academic
Author	Cappilli, Simone Chiricozzi, Andrea Antonelli, Flaminia Tassone, Francesco Zingarelli, Ruggiero Peris, Ketty
AuthorAffiliation	1 UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy 3 Largo A. Gemelli 8, 00168 Rome, Italy 2 Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
AuthorAffiliation_xml	– name: 2 Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168 Rome, Italy – name: 1 UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy – name: 3 Largo A. Gemelli 8, 00168 Rome, Italy
Author_xml	– sequence: 1 givenname: Francesco surname: Tassone fullname: Tassone, Francesco – sequence: 2 givenname: Simone orcidid: 0000-0001-9813-2391 surname: Cappilli fullname: Cappilli, Simone – sequence: 3 givenname: Flaminia surname: Antonelli fullname: Antonelli, Flaminia – sequence: 4 givenname: Ruggiero surname: Zingarelli fullname: Zingarelli, Ruggiero – sequence: 5 givenname: Andrea orcidid: 0000-0002-6739-0387 surname: Chiricozzi fullname: Chiricozzi, Andrea – sequence: 6 givenname: Ketty surname: Peris fullname: Peris, Ketty
BookMark	eNp1ks9v0zAUxy00xLayO8dIXDiQYcd2HHNAigKDSpN6KEwckKwXxymu0rhzkkn773lth6AVyAdb9uf7fX4_LslZH3pHyCtGrznX9N0DWOt7NzBKNRO5ekYuMqrylGv-_eyv8zm5GoY1pTuMF7l6Qc55jgIp5AX5UXZh66yHpIwORkgW1k4x-n6VQDu6mFSLu_nHlOnkbh8ORh_690mZLBHpXFq5Hqm3SRXDMKRLZ3fv0CXLcWoeX5LnLXSDu3raZ-Tbzaev1Zf0dvF5XpW3qZVcjKnVlglXuCxrRN0wKmsrpGZKaKl0y-saqMhpYVlT55iA5hoVFsBZxRVklM_I_ODbBFibbfQbiI8mgDf7ixBXBuLobedMU-gic6KW4HJhi0JrwRQtAM2FANmi14eD13aqN66xmF-E7sj0-KX3P80qPBgtqVRY7xl582QQw_3khtFs_GBd10HvwjSYTDGVF6pgGaKvT9B1mCKWb0_lmLPU9A-1AkzA923AuHZnakqFfcf_c4HU9T8oXI3beIuT03q8PxLkB4HdtS661lg_7tuLQt8ZRs1uzMzpmKGQngh_F-e_kl8MR9Tv
CitedBy_id	crossref_primary_10_1007_s00403_024_03583_z crossref_primary_10_1093_bjd_ljae055 crossref_primary_10_1007_s11845_023_03493_5 crossref_primary_10_7759_cureus_50133 crossref_primary_10_7774_cevr_2025_14_e34 crossref_primary_10_1080_14728222_2024_2344696
Cites_doi	10.1016/j.jaad.2021.03.092 10.1111/bjd.16808 10.1016/j.jfma.2022.03.006 10.1016/j.jaad.2021.09.002 10.1016/j.jdcr.2021.11.023 10.7774/cevr.2022.11.1.129 10.1016/j.clim.2021.108665 10.1016/j.biopha.2020.110542 10.1016/j.clim.2020.108480 10.1111/jocd.14581 10.1016/j.cct.2022.106700 10.1111/dth.15689 10.1007/s40257-017-0312-y 10.1111/ijd.16113 10.1016/j.jdcr.2022.04.022 10.1111/imm.13443 10.3390/vaccines8030554 10.1111/dth.15113 10.1016/j.jdin.2022.02.006 10.1111/jdv.17744 10.1111/jocd.14459
ContentType	Journal Article
Copyright	COPYRIGHT 2022 MDPI AG 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022 by the authors. 2022
Copyright_xml	– notice: COPYRIGHT 2022 MDPI AG – notice: 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022 by the authors. 2022
DBID	AAYXX CITATION 3V. 7T7 7XB 8FD 8FE 8FH 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU COVID DWQXO FR3 GNUQQ GUQSH HCIFZ LK8 M2O M7P MBDVC P64 PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA
DOI	10.3390/vaccines10091467
DatabaseName	CrossRef ProQuest Central (Corporate) Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (purchase pre-March 2016) Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College Coronavirus Research Database ProQuest Central Korea Engineering Research Database ProQuest Central Student ProQuest Research Library SciTech Premium Collection Biological Sciences ProQuest - Research Library Biological Science Database (ProQuest) Research Library (Corporate) Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic ProQuest Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef Publicly Available Content Database Research Library Prep ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Research Library Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition Coronavirus Research Database Biological Science Database ProQuest SciTech Collection Biotechnology and BioEngineering Abstracts ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic Publicly Available Content Database CrossRef
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: PIMPY name: ProQuest Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Pharmacy, Therapeutics, & Pharmacology
EISSN	2076-393X
ExternalDocumentID	oai_doaj_org_article_d8982e4b5ae64c889941708ac1d44a5f PMC9505739 A746717034 10_3390_vaccines10091467
GeographicLocations	Italy
GeographicLocations_xml	– name: Italy
GroupedDBID	53G 5VS 8FE 8FH 8G5 AADQD AAHBH AAYXX ABUWG ADBBV AEUYN AFFHD AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BBNVY BCNDV BENPR BHPHI BPHCQ CCPQU CITATION DIK DWQXO GNUQQ GROUPED_DOAJ GUQSH HCIFZ HYE IAO IHR ITC KQ8 LK8 M2O M48 M7P MODMG M~E OK1 PGMZT PHGZM PHGZT PIMPY PQGLB PQQKQ PROAC RNS RPM 3V. 7T7 7XB 8FD 8FK C1K COVID FR3 MBDVC P64 PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c534t-c9c14e8e22d4bd105bc4591749579f3bba04608c1db6386939c9ccaaec737a203
IEDL.DBID	DOA
ISICitedReferencesCount	8
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000856948100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2076-393X
IngestDate	Fri Oct 03 12:49:51 EDT 2025 Tue Nov 04 02:07:12 EST 2025 Wed Oct 01 14:10:54 EDT 2025 Fri Jul 25 10:03:32 EDT 2025 Tue Nov 11 11:09:50 EST 2025 Tue Nov 04 18:40:32 EST 2025 Tue Nov 18 21:48:46 EST 2025 Sat Nov 29 07:11:20 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	9
Language	English
License	Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c534t-c9c14e8e22d4bd105bc4591749579f3bba04608c1db6386939c9ccaaec737a203
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Case Study-2 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ORCID	0000-0001-9813-2391 0000-0002-6739-0387
OpenAccessLink	https://doaj.org/article/d8982e4b5ae64c889941708ac1d44a5f
PMID	36146545
PQID	2716608590
PQPubID	2032320
ParticipantIDs	doaj_primary_oai_doaj_org_article_d8982e4b5ae64c889941708ac1d44a5f pubmedcentral_primary_oai_pubmedcentral_nih_gov_9505739 proquest_miscellaneous_2717687812 proquest_journals_2716608590 gale_infotracmisc_A746717034 gale_infotracacademiconefile_A746717034 crossref_citationtrail_10_3390_vaccines10091467 crossref_primary_10_3390_vaccines10091467
PublicationCentury	2000
PublicationDate	2022-09-01
PublicationDateYYYYMMDD	2022-09-01
PublicationDate_xml	– month: 09 year: 2022 text: 2022-09-01 day: 01
PublicationDecade	2020
PublicationPlace	Basel
PublicationPlace_xml	– name: Basel
PublicationTitle	Vaccines (Basel)
PublicationYear	2022
Publisher	MDPI AG MDPI
Publisher_xml	– name: MDPI AG – name: MDPI
References	Rossi (ref_6) 2021; 20 Rajabi (ref_17) 2018; 179 Scollan (ref_4) 2022; 20 McMahon (ref_2) 2022; 86 Gallo (ref_5) 2022; 11 ref_12 McMahon (ref_1) 2021; 85 ref_21 Lee (ref_9) 2022; 61 Lo (ref_10) 2022; 25 Aram (ref_19) 2021; 34 Li (ref_22) 2020; 130 Jensen (ref_11) 2022; 115 Karadag (ref_18) 2021; 34 Richardson (ref_16) 2018; 19 Talotta (ref_15) 2021; 224 Chen (ref_13) 2022; 165 ref_8 Gambichler (ref_3) 2022; 36 Essam (ref_7) 2021; 20 Vojdani (ref_14) 2020; 217 Nguyen (ref_20) 2022; 7
References_xml	– volume: 85 start-page: 46 year: 2021 ident: ref_1 article-title: Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2021.03.092 – volume: 34 start-page: e14691 year: 2021 ident: ref_18 article-title: The impact of COVID-19 in patients with psoriasis: A multicenter study in Istanbul publication-title: Dermatol. Ther. – volume: 179 start-page: 1033 year: 2018 ident: ref_17 article-title: Alopecia areata: A review of disease pathogenesis publication-title: Br. J. Dermatol. doi: 10.1111/bjd.16808 – ident: ref_8 doi: 10.1016/j.jfma.2022.03.006 – volume: 86 start-page: 113 year: 2022 ident: ref_2 article-title: Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study publication-title: J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2021.09.002 – volume: 20 start-page: 1 year: 2022 ident: ref_4 article-title: Alopecia areata after SARS-CoV-2 vaccination publication-title: JAAD Case Rep. doi: 10.1016/j.jdcr.2021.11.023 – volume: 11 start-page: 129 year: 2022 ident: ref_5 article-title: Alopecia areata after COVID-19 vaccination publication-title: Clin. Exp. Vaccine Res. doi: 10.7774/cevr.2022.11.1.129 – volume: 224 start-page: 108665 year: 2021 ident: ref_15 article-title: Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to “potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases” publication-title: Clin. Immunol. doi: 10.1016/j.clim.2021.108665 – volume: 130 start-page: 110542 year: 2020 ident: ref_22 article-title: Role of the NLRP3 inflammasome in autoimmune diseases publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2020.110542 – volume: 217 start-page: 108480 year: 2020 ident: ref_14 article-title: Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases publication-title: Clin. Immunol. doi: 10.1016/j.clim.2020.108480 – volume: 20 start-page: 3753 year: 2021 ident: ref_6 article-title: Recurrence of alopecia areata after Covid-19 vaccination: A report of three cases in Italy publication-title: J. Cosmet. Dermatol. doi: 10.1111/jocd.14581 – volume: 115 start-page: 106700 year: 2022 ident: ref_11 article-title: COVID-19 vaccines: Considering sex differences in efficacy and safety publication-title: Contemp. Clin. Trials doi: 10.1016/j.cct.2022.106700 – ident: ref_12 doi: 10.1111/dth.15689 – volume: 19 start-page: 119 year: 2018 ident: ref_16 article-title: Evaluation of the Relationship between Alopecia Areata and Viral Antigen Exposure publication-title: Am. J. Clin. Dermatol. doi: 10.1007/s40257-017-0312-y – volume: 61 start-page: 634 year: 2022 ident: ref_9 article-title: Alopecia areata following COVID-19 vaccination: Vaccine-induced autoimmunity? publication-title: Int. J. Dermatol. doi: 10.1111/ijd.16113 – volume: 25 start-page: 25 year: 2022 ident: ref_10 article-title: Letter in Reply: Alopecia areata after SARS-CoV-2 vaccination publication-title: JAAD Case Rep. doi: 10.1016/j.jdcr.2022.04.022 – volume: 165 start-page: 386 year: 2022 ident: ref_13 article-title: New-onset autoimmune phenomena post-COVID-19 vaccination publication-title: Immunology doi: 10.1111/imm.13443 – ident: ref_21 doi: 10.3390/vaccines8030554 – volume: 34 start-page: e15113 year: 2021 ident: ref_19 article-title: COVID-19 and exacerbation of dermatological diseases: A review of the available literature publication-title: Dermatol. Ther. doi: 10.1111/dth.15113 – volume: 7 start-page: 67 year: 2022 ident: ref_20 article-title: Alopecia in patients with COVID-19: A systematic review and meta-analysis publication-title: JAAD Int. doi: 10.1016/j.jdin.2022.02.006 – volume: 36 start-page: 172 year: 2022 ident: ref_3 article-title: Cutaneous findings following COVID-19 vaccination: Review of world literature and own experience publication-title: J. Eur. Acad. Dermatol. Venereol. doi: 10.1111/jdv.17744 – volume: 20 start-page: 3727 year: 2021 ident: ref_7 article-title: Alopecia areata after ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca): A potential triggering factor? publication-title: J. Cosmet. Dermatol. doi: 10.1111/jocd.14459
SSID	ssj0000913867
Score	2.2601433
Snippet	Limited data concerning the development of autoimmune skin diseases after COVID-19 vaccination are currently available. Recently, a few reports described the... BackgroundLimited data concerning the development of autoimmune skin diseases after COVID-19 vaccination are currently available. Recently, a few reports...
SourceID	doaj pubmedcentral proquest gale crossref
SourceType	Open Website Open Access Repository Aggregation Database Enrichment Source Index Database
StartPage	1467
SubjectTerms	Alopecia alopecia areata Autoimmune diseases Baldness Case Report Coronaviruses Corticoids Corticosteroids COVID-19 COVID-19 vaccines Cross-sectional studies Disease Dosage and administration Hair loss Health services Immunotherapy Medical records Minoxidil Pandemics Patient outcomes Patients Prevention Regrowth Risk factors SARS-CoV-2 Scalp Severe acute respiratory syndrome coronavirus 2 Skin diseases Thyroid gland Tofacitinib vaccine
SummonAdditionalLinks	– databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELeg44EXvhEZAxkJDSHVahM7scML6somkFCp2Jj2gBTZjgOTqmRLukn977lz0pYMaS-8xufGV58v9-XfEfI2Fy4ZR3nCTGIUEzoqmBbcstwIwQVG3gp_UfirnM3U2Vk67wJuTVdWudaJXlHnlcUY-SgCwz5BNK7xx4tLhl2jMLvatdC4S3YQqUwMyM7B4Wz-fRNlQdRLlcg2P8nBvx9da4sZ6ybEsba9_PZ75GH7_1XONwsm__oCHT3837U_Ig8625NOWmF5TO648gnZn7fg1ashPdnexWqGdJ_Ot7DWq6fk52RR-Wb18AOgwDVFgOIaw4LUNxqn02-nXz6xMKWnnnm_5R_ohB4DycIxjCO7ekin-D-wY18ChsvBSsbVM_Lj6PBk-pl1vRmYjblYMpvaUDjloigXJgcjzVgRg-snMO1XcGM0ZlyVDXMDJzxJeQozrNbOSi51NObPyaCsSveCULDYiliKQjrwBVVRaGOsjgs0XUKZKxGQ0XqHMtsBl2P_jEUGDgzuaXZzTwPyfjPjogXtuIX2ADd9Q4dw2_5BVf_KutOb5SpVkRMm1i4RVoGPKkI5VhrYEwLWGpB3KDIZKgVYmtXd3QZgEOG1sgk2dYEZHJjZ61HCYbb94bUEZZ0yabKt-ATkzWYYZ2KBXOmqK08DjqMEcy0gsiesPc76I-X5bw8onqKXytPd21_-ktyP8O6HL7DbI4NlfeVekXv2enne1K-7k_cHw2g6YQ priority: 102 providerName: ProQuest
Title	Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study
URI	https://www.proquest.com/docview/2716608590 https://www.proquest.com/docview/2717687812 https://pubmed.ncbi.nlm.nih.gov/PMC9505739 https://doaj.org/article/d8982e4b5ae64c889941708ac1d44a5f
Volume	10
WOSCitedRecordID	wos000856948100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Open Access Journals customDbUrl: eissn: 2076-393X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000913867 issn: 2076-393X databaseCode: DOA dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2076-393X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000913867 issn: 2076-393X databaseCode: M~E dateStart: 20130101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 2076-393X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000913867 issn: 2076-393X databaseCode: M7P dateStart: 20130301 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2076-393X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000913867 issn: 2076-393X databaseCode: BENPR dateStart: 20130301 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content Database customDbUrl: eissn: 2076-393X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000913867 issn: 2076-393X databaseCode: PIMPY dateStart: 20130301 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Research Library customDbUrl: eissn: 2076-393X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000913867 issn: 2076-393X databaseCode: M2O dateStart: 20130301 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Rb9MwELZg44EXBANEYFSehIaQarWJndjhrSudmMS6iI2pSEiR7ThiUpWitpvUF347d07WNpsEL7z4oXeubN_5cmefvyPkXSFc0o-KhJnEKCZ0VDItuGWFEYILPHkr_UPhL3I8VpNJmm2V-sKcsBoeuF64XqFSFTlhYu0SYRWEByKUfaVtWAih4xKtL3g9W8GUt8FpyFUi63tJDnF970ZbvKlehEiry8pvvkMerv--Ub6bKLn15Tl-Sp40LiMd1EN9Rh64ao8cZjXm9KpLLzZPqBZdekizDRr16jn5MZjOfI15-AOwu5oirvAcT_Oorw9Oh2eXJ59YmNJLP3YvqY90QM-BZeoYHv-6eZcOcRrs3Gdu4XAwAXH1gnw7Hl0MP7OmpAKzMRdLZlMbCqdcFBXCFOBbGStiiNgE3taV3BiNF6UKFtfAxkxSnkIPq7Wzkksd9flLslPNKveKUHC0yliKUjoI4VRZamMsyAM9jlAWSgSkd7vAuW3wxrHsxTSHuANFkt8VSUA-rHv8qrE2_sJ7hDJb8yFKtv8BdCdvdCf_l-4E5D1KPMe9DEOzunmSABNEVKx8gLVYoAeHyey3OGEP2jb5VmfyxgYs8ghC0QTx4_oBOViTsSfmtVVudu15IN6T4GUFRLZ0rTWzNqW6-ulxwFMMLnn6-n8sxRvyOMKHHT57bp_sLOfX7i15ZG-WV4t5hzyUE9Uhu0ejcfa147catKfRGbYyw_b3COjZyWn2_Q_vuTIa
linkProvider	Directory of Open Access Journals
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1fb9MwELfGQGIv_EcUBhgJhpBqtbGdxEFCqHRMq1ZKpXXTHpCC7ThjUpWWthvql-IzcuekLR3S3vbAa3xOfM7P57vz-Y6Q15l0UZNnETORUUxqnjMthWWZkVJI9Lzl_qJwN-711MlJ0t8gvxd3YTCsciETvaDORhZ95A0Oin2E2biaH8c_GVaNwtPVRQmNEhYHbv4LTLbph84u_N83nO99HrT3WVVVgNlQyBmziQ2kU47zTJoM1AtjZQhGi8QDq1wYo_GsUNkgM4DNKBEJ9LBaOxuLWPOmgPfeIDdBjeDKhwr2lz4dzLGporg8DRUiaTYutMXz8WmAbWUx-9Xu54sE_LsVXA7P_Gu_27v7v83UPXKn0qxpq1wK98mGKx6QnX6Zmntep4PVTbNpne7Q_ipp9_wh-dYajsYOgAovgO1JU0y_PEGnJ_Vl1Gn763FnlwUJPfaT7QH9nrboIZAMHUMvuZvUaRvnnR36ADccDsZpzh-Ro2vh_DHZLEaFe0Io6KN5GMs8dmDpqjzXxlgd5qiYBXGmZI00FohIbZWWHauDDFMwzxBD6WUM1ci7ZY9xmZLkCtpPCLIlHSYT9w9Gk9O0kk1pphLFnTShdpG0CixwGcRNpYE9KWGsNfIWIZqiyIOhWV3d3AAGMXlY2sKSNdBDADPba5Qgqux68wKxaSUqp-kKrjXyatmMPTH8r3Cjc08DZnEMymiNxGuLY42z9Zbi7IdPl56gDS6Sp1d__CW5vT_40k27nd7BM7LF8ZaLDyXcJpuzybl7Tm7Zi9nZdPLCr3lKvl_30vkDvtmVsg
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwELfGhhAvfCMKA4wEQ0i12sRO7CAh1LWrqDaViH1oD0jBdhyYVLWl7Yb6r_HXceekLR3S3vbAa22nvuTn853v_DtCXufCxc0wj5mJjWJChwXTgluWGyG4wJO3wl8UPpD9vjo9TdIN8ntxFwbTKhc60SvqfGTxjLwRgmEfIxtXs1FUaRFpp_tx_JNhBSmMtC7KaZQQ2XfzX-C-TT_0OvCt34Rhd--o_YlVFQaYjbiYMZvYQDjlwjAXJgdTw1gRgQMjMHhVcGM0xg2VDXIDOI0TnsAIq7WzkksdNjk89wbZkmBkwOra2t3rp1-WJzzIuKliWcZGOYeJX2iL0fJpgG1lafvVXuhLBvy7MVxO1vxr9-ve_Z_f2z1yp7K5aatcJPfJhhs-IDtpSdo9r9Oj1R20aZ3u0HRF5z1_SL62BqOxAwjDA2Dj0hSJmSd4HEp9gXXa_nzS67AgoSf-xXuov6cteghdBo7h-bmb1GkbvwE79KlvOB3M4Jw_IsfXIvljsjkcDd0TQsFSLSIpCunAB1ZFoY2xOirQZAtkrkSNNBboyGxF2I51QwYZOG6Ip-wynmrk3XLEuCQruaLvLgJu2Q9pxv0Po8n3rNJaWa4SFTphIu1iYRX45iKQTaVBPCFgrjXyFuGaoTKEqVld3ekAAZFWLGthMRsYwUGY7bWeoMTsevMCvVmlRKfZCro18mrZjCMxMXDoRue-DzjMEszUGpFrC2VNsvWW4dkPT6SeoHfOk6dX__lLcgtWTHbQ6-8_I7dDvP7icwy3yeZscu6ek5v2YnY2nbyoFAAl36577fwBRhmfwg
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Alopecia+Areata+Occurring+after+COVID-19+Vaccination%3A+A+Single-Center%2C+Cross-Sectional+Study&rft.jtitle=Vaccines+%28Basel%29&rft.au=Tassone%2C+Francesco&rft.au=Cappilli%2C+Simone&rft.au=Antonelli%2C+Flaminia&rft.au=Zingarelli%2C+Ruggiero&rft.date=2022-09-01&rft.issn=2076-393X&rft.eissn=2076-393X&rft.volume=10&rft.issue=9&rft.spage=1467&rft_id=info:doi/10.3390%2Fvaccines10091467&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_vaccines10091467
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2076-393X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2076-393X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2076-393X&client=summon